Protalix BioTherapeutics 将来の成長
Future 基準チェック /06
Protalix BioTherapeuticsの収益と利益はそれぞれ年間6.1%と69.6%減少すると予測されていますが、EPS は年間68.9% 減少すると予測されています。
主要情報
-69.6%
収益成長率
-68.94%
EPS成長率
| Biotechs 収益成長 | 25.4% |
| 収益成長率 | -6.1% |
| 将来の株主資本利益率 | n/a |
| アナリストカバレッジ | Low |
| 最終更新日 | 14 May 2026 |
今後の成長に関する最新情報
Recent updates
ナラティブの更新 • May 11
PLX: Extended Dosing Approval And 2026 Outlook Will Support Further Upside
Analysts kept their $11.00 price target on Protalix BioTherapeutics unchanged, citing only minor adjustments in discount rate, revenue growth, profit margin, and future P/E assumptions that did not materially alter their overall view of the stock. What's in the News The European Commission approved a 2 mg/kg every 4 weeks dosing regimen for pegunigalsidase alfa (Elfabrio) in adults with Fabry disease who are stable on enzyme replacement therapy, extending the infusion interval from every 2 weeks to every 4 weeks (Key Developments).ナラティブの更新 • Apr 26
PLX: New Dosing Approval And 2026 Revenue Outlook Will Support Upside
Analysts now set Protalix BioTherapeutics' price target at $11.00. The unchanged level reflects only minimal tweaks to inputs such as the discount rate, long term revenue growth, profit margin assumptions and future P/E expectations.ナラティブの更新 • Apr 09
PLX: New Dosing Approval And 2026 Revenue Outlook Will Support Upside
Analysts have maintained their $11.00 price target for Protalix BioTherapeutics, citing relatively stable assumptions around fair value, discount rate, revenue growth, profit margin and future P/E as the basis for keeping their outlook unchanged. What's in the News The European Commission approves a 2 mg/kg every four weeks dosing regimen for pegunigalsidase alfa in adults with Fabry disease who are stable on enzyme replacement therapy, extending the infusion interval from every two weeks to every four weeks (Key Developments).ナラティブの更新 • Mar 26
PLX: New Dosing Approval And 2026 Outlook Will Support Undervalued Upside
Analysts kept their $11.00 price target on Protalix BioTherapeutics unchanged, highlighting revised assumptions for revenue growth, profit margins, the discount rate and future P/E as key drivers behind their updated model. What's in the News Protalix BioTherapeutics issued 2026 total revenue guidance of approximately $78.0 million to $83.0 million, which includes a $25.0 million milestone payment from Chiesi tied to regulatory progress for Elfabrio (company guidance).ナラティブの更新 • Mar 09
PLX: Extended Fabry Dosing Will Support Undervalued Long Term Outlook
Analysts have reiterated an $11.00 price target for Protalix BioTherapeutics, citing only slight tweaks to model inputs such as the discount rate, long-term revenue growth, profit margins, and future P/E assumptions rather than any major shift in their overall view. What's in the News Chiesi Global Rare Diseases and Protalix BioTherapeutics reported that the European Medicines Agency's Committee for Medicinal Product for Human Use issued a positive opinion recommending approval of a 2 mg/kg every 4 weeks dosing regimen of pegunigalsidase alfa for adult Fabry patients who are stable on enzyme replacement therapy (Key Developments).ナラティブの更新 • Feb 23
PLX: Fabry Dosing Extension Will Support Undervalued Long Term Outlook
Analysts are maintaining their $11.00 price target for Protalix BioTherapeutics while slightly refining core modeling inputs such as the discount rate, long term revenue growth, profit margin and future P/E assumptions to better align with their updated risk and earnings outlook. What's in the News CHMP of the EMA issued a positive opinion recommending approval of a 2 mg/kg every 4 weeks dosing regimen for pegunigalsidase alfa in adult Fabry disease patients who are stable on enzyme replacement therapy, potentially giving eligible patients a longer interval between infusions (Product related announcement).ナラティブの更新 • Feb 08
PLX: Renal ASO Pipeline And Fabry Dosing Expansion Will Drive Upside
Analysts have maintained their price target for Protalix BioTherapeutics at US$11.00, citing a combination of updated assumptions regarding the discount rate, revenue growth, profit margins, and a higher future P/E multiple as reasons to keep their existing valuation view. What's in the News Chiesi Global Rare Diseases and Protalix BioTherapeutics reported that the EMA's Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of a 2 mg/kg every 4 weeks dosing regimen of pegunigalsidase alfa for adult Fabry patients who are stable on enzyme replacement therapy, aiming to extend time between infusions so patients can focus more on daily life (Key Developments).ナラティブの更新 • Jan 24
PLX: Renal ASO Collaboration Will Drive Next Phase Of Upside Potential
Analysts have maintained their US$11.00 price target for Protalix BioTherapeutics, citing only slight adjustments to their discount rate, long term revenue growth, profit margin assumptions and future P/E outlook, rather than any major shift in their thesis. What's in the News Protalix BioTherapeutics and Secarna Pharmaceuticals entered a collaboration and option agreement to discover antisense oligonucleotide therapies targeting rare renal indications, with Secarna using its OligoCreator platform to design and profile candidates and Protalix selecting the biological targets (Key Developments).ナラティブの更新 • Jan 10
PLX: Renal Collaboration Agreement Will Drive Next Phase Of Upside Potential
Analysts have maintained their fair value estimate for Protalix BioTherapeutics at US$11.00. This reflects only minor adjustments to assumptions around discount rate, revenue growth, profit margins and future P/E that do not materially change their overall view.ナラティブの更新 • Dec 16
PLX: European Label Expansion Review Will Drive Next Phase Of Upside Potential
Analysts have nudged their price target on Protalix BioTherapeutics slightly higher to $11.00, reflecting marginal adjustments to discount rate, long term growth, and profitability assumptions, while maintaining a broadly consistent valuation framework. What's in the News Chiesi Global Rare Diseases and Protalix BioTherapeutics requested re examination of the EMA CHMP negative opinion on adding a once every 4 weeks 2 mg/kg Elfabrio dosing regimen to the currently approved every 2 weeks regimen, seeking broader label flexibility in Europe (Key Developments) Safety data from Elfabrio clinical trials highlighted hypersensitivity reactions in 14 percent of treated patients and anaphylaxis in 3 percent, underscoring the need for careful infusion monitoring and potential dose adjustments (Key Developments) Additional clinical observations included infusion associated reactions in 29 percent of Elfabrio patients and a reported case of membranoproliferative glomerulonephritis, prompting recommendations to monitor renal function and infusion related symptoms (Key Developments) Protalix BioTherapeutics was added to the S&P Global BMI Index, potentially increasing its visibility and accessibility to global institutional investors (Key Developments) Valuation Changes Fair value estimate maintained at $11.00 per share, indicating no change to the analyst target price.ナラティブの更新 • Dec 02
PLX: European Regulatory Review Will Unlock Next Phase Of Upside Potential
Analysts have lowered their price target for Protalix BioTherapeutics from $12.50 to $11.00, citing a slight reduction in expected revenue growth and profit margins. What's in the News Protalix BioTherapeutics and Chiesi Global Rare Diseases have requested a re-examination of the negative opinion by the European Medicines Agency regarding the new dosing regimen for Elfabrio.ナラティブの更新 • Nov 18
PLX: European Review Process Will Drive Next Phase Of Momentum
Analysts have lowered their price target for Protalix BioTherapeutics from $14.00 to $12.50. They cite more conservative expectations regarding revenue growth and profit margins.
新しいナラティブ • May 19
Protalix BioTherapeutics aims for $3.20 by year-end amidst strong revenue growth
As of right now the stock as a current yield of about 2.42%, with a return on equity of about 6.79%. So a bit off of my goals of at least 5% and 10%. However over the last 3 years revenue has grown on
新しいナラティブ • Apr 29
PRX-115 Trials And Elfabrio Launch Will Open Future Markets
Successful Phase II trials and Chiesi's involvement with Elfabrio could drive growth through new marketable products and increased market adoption.分析記事 • Feb 22
Analysts Expect Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) To Breakeven Soon
We feel now is a pretty good time to analyse Protalix BioTherapeutics, Inc.'s ( NYSEMKT:PLX ) business as it appears...分析記事 • Jan 14
Have Insiders Been Buying Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares This Year?
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...分析記事 • Dec 10
Could The Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Ownership Structure Tell Us Something Useful?
A look at the shareholders of Protalix BioTherapeutics, Inc. ( NYSEMKT:PLX ) can tell us which group is most powerful...業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2028 | 67 | 1 | N/A | N/A | 1 |
| 12/31/2027 | 68 | 5 | N/A | N/A | 2 |
| 12/31/2026 | 79 | 12 | N/A | N/A | 2 |
| 3/31/2026 | 76 | 15 | 13 | 15 | N/A |
| 12/31/2025 | 53 | -7 | -14 | -12 | N/A |
| 9/30/2025 | 62 | 5 | -12 | -10 | N/A |
| 6/30/2025 | 62 | 6 | -3 | -2 | N/A |
| 3/31/2025 | 60 | 4 | -2 | -1 | N/A |
| 12/31/2024 | 53 | 3 | 7 | 9 | N/A |
| 9/30/2024 | 46 | -10 | 7 | 8 | N/A |
| 6/30/2024 | 38 | -15 | -4 | -3 | N/A |
| 3/31/2024 | 60 | 7 | 4 | 6 | N/A |
| 12/31/2023 | 65 | 8 | -2 | -1 | N/A |
| 9/30/2023 | 64 | 11 | -9 | -8 | N/A |
| 6/30/2023 | 67 | 9 | -11 | -10 | N/A |
| 3/31/2023 | 41 | -16 | -23 | -22 | N/A |
| 12/31/2022 | 48 | -15 | -26 | -25 | N/A |
| 9/30/2022 | 48 | -18 | -28 | -27 | N/A |
| 6/30/2022 | 45 | -18 | -21 | -20 | N/A |
| 3/31/2022 | 43 | -24 | -8 | -6 | N/A |
| 12/31/2021 | 38 | -28 | -12 | -10 | N/A |
| 9/30/2021 | 49 | -21 | -14 | -13 | N/A |
| 6/30/2021 | 48 | -21 | -16 | -14 | N/A |
| 3/31/2021 | 53 | -14 | -30 | -29 | N/A |
| 12/31/2020 | 63 | -7 | -27 | -26 | N/A |
| 9/30/2020 | 61 | -7 | -23 | -22 | N/A |
| 6/30/2020 | 65 | -6 | -23 | -22 | N/A |
| 3/31/2020 | 66 | -9 | -20 | -19 | N/A |
| 12/31/2019 | 55 | -18 | N/A | -19 | N/A |
| 9/30/2019 | 47 | -24 | N/A | -20 | N/A |
| 6/30/2019 | 45 | -26 | N/A | -3 | N/A |
| 3/31/2019 | 38 | -26 | N/A | -6 | N/A |
| 12/31/2018 | 34 | -26 | N/A | -8 | N/A |
| 9/30/2018 | 28 | -34 | N/A | 14 | N/A |
| 6/30/2018 | 23 | -40 | N/A | -10 | N/A |
| 3/31/2018 | 25 | -32 | N/A | -11 | N/A |
| 12/31/2017 | 21 | -83 | N/A | -10 | N/A |
| 9/30/2017 | 19 | -73 | N/A | -35 | N/A |
| 6/30/2017 | 16 | -69 | N/A | -28 | N/A |
| 3/31/2017 | 11 | -80 | N/A | -31 | N/A |
| 12/31/2016 | 9 | -29 | N/A | -32 | N/A |
| 9/30/2016 | 7 | -35 | N/A | -29 | N/A |
| 6/30/2016 | 4 | -34 | N/A | -34 | N/A |
| 3/31/2016 | 3 | -29 | N/A | -27 | N/A |
| 12/31/2015 | 4 | -27 | N/A | -24 | N/A |
| 9/30/2015 | -6 | -31 | N/A | -25 | N/A |
| 6/30/2015 | -4 | -33 | N/A | -26 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: PLXの収益は今後 3 年間で減少すると予測されています (年間-69.6% )。
収益対市場: PLXの収益は今後 3 年間で減少すると予測されています (年間-69.6% )。
高成長収益: PLXの収益は今後 3 年間で減少すると予測されています。
収益対市場: PLXの収益は今後 3 年間で減少すると予想されています (年間-6.1% )。
高い収益成長: PLXの収益は今後 3 年間で減少すると予測されています (年間-6.1% )。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: PLXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/21 15:36 |
| 終値 | 2026/05/21 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Protalix BioTherapeutics, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。8
| アナリスト | 機関 |
|---|---|
| Ritu Baral | Canaccord Genuity |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Peter Welford | Jefferies LLC |